COVID-19 Disease
Conditions
Keywords
COVID-19, SARS-CoV-2 viral infection, VEGF and sFlt-1 levels
Brief summary
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.
Detailed description
When patients are sick with other lung infections (pneumonias) caused by viruses or bacteria there are changes in a pathway that regulates the "leakiness" the tiny airspaces inside the lungs. Even bigger changes in this pathway are seen when patients develop severe breathing difficulties (acute respiratory distress syndrome) similar to what is seen in patients who get really sick with COVID-19 disease. There are important changes in this pathway that occur in patients who have preexisting cardiovascular (heart) disease who do not have lung infections. The investigator will evaluate these levels in patients with COVID-19 because the investigator believes that this baseline difference in pathway regulation may be one reason patients with heart disease who contract COVID-19 get sicker than patients without heart or vascular disease. The investigator will also assess the levels of components of this pathway in patients who are less sick with those who became sick enough to require a tube to help them breathe because this is important to determine if COVID-19 lung disease has a similar effect on this pathway as other lung infections like flu and bacterial pneumonias.
Interventions
None listed
Sponsors
University of Alabama at Birmingham
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Positive test for COVID-19 (SARS-CoV-2 infection) * \>=18 years * Blood (plasma) specimen(s) available in the CCTS biorepository
Exclusion criteria
* \<18 years * Lack of blood specimen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory Assays | 7-14 days after symptom onset | The primary outcome measure is the ratio of soluble fms-like tyrosine kinase receptor-1 (sFlt-1) to vascular endothelial growth factor (VEGF) which will be obtained using an immunoassay on blood samples. The specimens will be analyzed using enzyme-linked immunosorbent assay and reported as a ratio |
| VEGF-A | 7-14 days after symptom onset | Plasma samples will be analyzed to measure VEGF-A |
| VEGF-C | 7-14 days after symptom onset | Plasma samples will be analyzed to measure VEGF-C |
| VEGF-D | 7-14 days after symptom onset | Plasma samples will be analyzed to measure VEGF-D |
| Tie-2 | 7-14 days after symptom onset | Plasma samples will be analyzed to measure Tie-2 |
| Flt-1 | 7-14 days after symptom onset | Plasma samples will be analyzed to measure Flt-1 |
| PlGF | 7-14 days after symptom onset | Plasma samples will be analyzed to measure PlGF |
| FGF | 7-14 days after symptom onset | Plasma samples will be analyzed to measure FGF |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDylan Addis, MD
University of Alabama at Birmingham
Outcome results
None listed